Hi Ajostu. Unfortunately I can’t make it to the AGM…but I would love to know:
-Neuren has regularly stated they understand the extent of resources required to ensure trofinetide is commercialised as quickly as possible. Does Neuren favour a licensing approach or would an outright sale of Neuren also be considered?
-What has Leerink been instructed to undertake?
-Current cash projects show Neuren will need cash by the end of the year. Is it expected that a deal will be done before a more typical capital raise is required?
-Is Neuren intending to fill the role vacated by Joe Horrigan?
-Did Neuren apply for Breakthrough Therapy Status for Fragile X?
-Has Neuren imposed any social media restrictions on participants in the Rett Phase 2b trial?
-What is the next step for NNZ – 2591 and when will that occur?
Hi Ajostu. Unfortunately I can’t make it to the AGM…but I would...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.34 |
Change
-0.410(2.60%) |
Mkt cap ! $1.960B | |||
| Open | High | Low | Value | Volume |
| $15.88 | $15.93 | $15.34 | $6.463M | 415.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6044 | $15.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.57 | 1411 | 2 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |